[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"7a52caf1-0dfe-4289-a790-01f8d7b2993f","acronym":"DUAL-CAR-NK-GB","url":"https://clinicaltrials.gov/study/NCT07480941","created_at":"2026-03-28T01:39:30.783Z","updated_at":"2026-03-28T01:39:30.783Z","phase":"Phase 1","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","source_id_and_acronym":"NCT07480941 - DUAL-CAR-NK-GB","lead_sponsor":"Beijing Biotech","biomarkers":" EGFR • CD276 • IL13RA2","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • CD276 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/02/2026","start_date":" 02/02/2026","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 03/17/2028","study_completion_date":" 03/17/2028","last_update_posted":"2026-03-18"},{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"4bb42519-747d-45f0-98ad-774255094bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07109518","created_at":"2025-08-09T14:25:49.588Z","updated_at":"2025-08-09T14:25:49.588Z","phase":"Phase 1","brief_title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","source_id_and_acronym":"NCT07109518","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2025","start_date":" 06/28/2025","primary_txt":" Primary completion: 06/28/2028","primary_completion_date":" 06/28/2028","study_txt":" Completion: 06/28/2030","study_completion_date":" 06/28/2030","last_update_posted":"2025-08-07"},{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"8928481a-724a-435c-8656-726fa0e4aab3","acronym":"GLYCAR","url":"https://clinicaltrials.gov/study/NCT02905188","created_at":"2021-03-12T22:55:55.778Z","updated_at":"2025-02-25T12:26:31.981Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","source_id_and_acronym":"NCT02905188 - GLYCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2025-02-24"},{"id":"ef9f9bd0-273f-42be-ab92-31c003721bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861106","created_at":"2021-01-18T08:19:16.098Z","updated_at":"2025-02-25T12:26:02.331Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","source_id_and_acronym":"NCT01861106","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GATA2","pipe":" | ","alterations":" GATA2 mutation","tags":["GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 07/24/2013","start_date":" 07/24/2013","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-24"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"168840e4-a367-4523-bec5-a87bb18a9b81","acronym":"NT-175-201","url":"https://clinicaltrials.gov/study/NCT05877599","created_at":"2023-05-26T15:07:05.809Z","updated_at":"2025-02-25T13:55:14.477Z","phase":"Phase 1","brief_title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","source_id_and_acronym":"NCT05877599 - NT-175-201","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • HLA-A","pipe":" | ","alterations":" TP53 mutation • HLA-A*02:01","tags":["TP53 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NT-175"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 08/01/2039","study_completion_date":" 08/01/2039","last_update_posted":"2025-02-20"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"ff4e0c3b-845b-4c81-ada0-12dd4b76209c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06777979","created_at":"2025-02-25T13:57:28.881Z","updated_at":"2025-02-25T13:57:28.881Z","phase":"Phase 1","brief_title":"CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06777979","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-20"},{"id":"838ef8af-7db3-4078-892e-5e0008843be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01005745","created_at":"2023-12-09T15:40:19.931Z","updated_at":"2025-02-25T13:59:46.111Z","phase":"","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01005745","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/20/2009","start_date":" 10/20/2009","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-19"},{"id":"d5afe40d-858e-4e8c-a552-782c25a7e99d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834529","created_at":"2025-02-25T14:05:59.231Z","updated_at":"2025-02-25T14:05:59.231Z","phase":"Phase 1/2","brief_title":"CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT06834529","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/20/2025","start_date":" 01/20/2025","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-19"},{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"f8d87fba-1ad4-4662-baab-e93772837874","acronym":"Agni-01","url":"https://clinicaltrials.gov/study/NCT06060613","created_at":"2023-09-29T19:11:12.291Z","updated_at":"2025-02-25T14:03:51.690Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","source_id_and_acronym":"NCT06060613 - Agni-01","lead_sponsor":"Obsidian Therapeutics, Inc.","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • OBX-115"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-02-19"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"01487ba7-9d61-4bb2-b7ab-9b09a185d399","acronym":"","url":"https://clinicaltrials.gov/study/NCT06609928","created_at":"2025-02-25T14:43:34.775Z","updated_at":"2025-02-25T14:43:34.775Z","phase":"Phase 1","brief_title":"FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06609928","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/12/2025","start_date":" 03/12/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2042","study_completion_date":" 10/01/2042","last_update_posted":"2025-02-14"},{"id":"0b525e9d-4ff9-4d49-a886-decd1a174c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04643574","created_at":"2021-01-19T20:39:09.813Z","updated_at":"2025-02-25T14:40:41.852Z","phase":"Phase 1","brief_title":"NeoTIL in Advanced Solid Tumors","source_id_and_acronym":"NCT04643574","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" TNFA • IL2","pipe":"","alterations":" ","tags":["TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-14"},{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"}]